C4 Therapeutics CCCC

$ 4.26 6.26%

Quarterly report 2024-Q3
added 10-31-2024

C4 Therapeutics Balance Sheet 2011-2024 | CCCC

Annual Balance Sheet C4 Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-15.9 M	-64 M	-171 M	-76.8 M	-21.8 M	-	-	-	-	-	-	-
Long Term Debt	-	9.2 M	10.8 M	10.1 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	5.22 M	4.7 M	1.33 M	1.04 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	75.5 M	197 M	202 M	-	-	-	-	-	-	-
Total Current Liabilities	42.8 M	44.5 M	51.2 M	43.9 M	-	-	-	-	-	-	-	-	-
Total Liabilities	130 M	142 M	117 M	119 M	230 M	226 M	-	-	-	-	-	-	-
Deferred Revenue	15.5 M	16.6 M	31.8 M	27.6 M	20.7 M	19.1 M	-	-	-	-	-	-	-
Retained Earnings	-528 M	-396 M	-268 M	-184 M	-117 M	-83.4 M	-	-	-	-	-	-	-
Total Assets	376 M	431 M	507 M	400 M	118 M	146 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	127 M	29.8 M	76.1 M	182 M	90.5 M	38.9 M	-	-	-	-	-	-	-
Book Value	246 M	289 M	390 M	281 M	-112 M	-79.8 M	-	-	-	-	-	-	-
Total Shareholders Equity	246 M	289 M	390 M	281 M	-112 M	-79.8 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet C4 Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	61.5 M	62.9 M	64.4 M	65.8 M	-	-	8.62 M	9.2 M	9.05 M	-	10.2 M	10.8 M	10.6 M	10.4 M	10.2 M	10.1 M	10.1 M	10.1 M	10.1 M	12.9 M	12.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	133 M	134 M	140 M	130 M	117 M	141 M	134 M	142 M	143 M	-	151 M	117 M	109 M	112 M	110 M	119 M	119 M	119 M	119 M	119 M	119 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	20.8 M	36.6 M	35.1 M	15.5 M	8.42 M	14 M	14.9 M	16.6 M	18.1 M	-	31.3 M	31.8 M	32.3 M	28.7 M	26.6 M	27.6 M	27.6 M	27.6 M	27.6 M	20.7 M	20.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-599 M	-574 M	-557 M	-528 M	-494 M	-467 M	-431 M	-396 M	-359 M	-	-299 M	-268 M	-252 M	-227 M	-205 M	-184 M	-184 M	-184 M	-184 M	-117 M	-117 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	376 M	381 M	398 M	376 M	333 M	375 M	396 M	431 M	461 M	-	515 M	507 M	508 M	528 M	374 M	400 M	400 M	400 M	400 M	118 M	118 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	59.6 M	73.1 M	89.7 M	127 M	61 M	44.9 M	49.5 M	29.8 M	49.6 M	57.3 M	46 M	76.1 M	163 M	281 M	94.9 M	182 M	182 M	182 M	182 M	90.5 M	90.5 M	-	-	38.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	243 M	247 M	258 M	246 M	216 M	234 M	262 M	289 M	318 M	-	365 M	390 M	399 M	416 M	264 M	281 M	281 M	281 M	281 M	-968 K	-968 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	243 M	247 M	258 M	246 M	216 M	234 M	262 M	289 M	318 M	345 M	365 M	390 M	399 M	416 M	264 M	281 M	281 M	281 M	281 M	-112 M	-112 M	-93.4 M	-	-79.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency